Literature DB >> 16148124

Differential regulation of CD40-mediated TNF receptor-associated factor degradation in B lymphocytes.

Carissa R Moore1, Gail A Bishop.   

Abstract

Engagement of CD40 on murine B cells by its ligand CD154 induces the binding of TNFR-associated factors (TRAFs) 1, 2, 3, and 6, followed by the rapid degradation of TRAFs 2 and 3. TRAF degradation occurs in response to signaling by other TNFR superfamily members, and is likely to be a normal regulatory component of signaling by this receptor family. In this study, we found that receptor-induced TRAF degradation limits TRAF2-dependent CD40 signals to murine B cells. However, TRAFs 1 and 6 are not degraded in response to CD40 engagement, despite their association with CD40. To better understand the mechanisms underlying differential TRAF degradation, mixed protein domain TRAF chimeras were analyzed in murine B cells. Chimeras containing the TRAF2 zinc (Zn) domains induced effective degradation, if attached to a TRAF domain that binds to the PXQXT motif of CD40. However, the Zn domains of TRAF3 and TRAF6 could not induce degradation in response to CD40, regardless of the TRAF domains to which they were attached. Our data indicate that TRAF2 serves as the master regulator of TRAF degradation in response to CD40 signaling, and this function is dependent upon both the TRAF Zn domains and receptor binding position.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148124     DOI: 10.4049/jimmunol.175.6.3780

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation.

Authors:  Li-Fan Lu; Cory L Ahonen; Evan F Lind; Vanitha S Raman; W James Cook; Ling-Li Lin; Randolph J Noelle
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

Review 2.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 3.  How do pleiotropic kinase hubs mediate specific signaling by TNFR superfamily members?

Authors:  Bärbel Schröfelbauer; Alexander Hoffmann
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 4.  Roles of TRAF molecules in B lymphocyte function.

Authors:  Ping Xie; Zachary J Kraus; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-21       Impact factor: 7.638

5.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 6.  NF-κB inducing kinase: a key regulator in the immune system and in cancer.

Authors:  Yee Mon Thu; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-03       Impact factor: 7.638

Review 7.  TRAF family molecules in T cells: Multiple receptors and functions.

Authors:  Tina Arkee; Gail A Bishop
Journal:  J Leukoc Biol       Date:  2019-11-21       Impact factor: 4.962

Review 8.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

9.  cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand.

Authors:  Alban Dupoux; Jessy Cartier; Séverine Cathelin; Rodolphe Filomenko; Eric Solary; Laurence Dubrez-Daloz
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

10.  A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.

Authors:  Joanne M Hildebrand; Zhenghua Luo; Michelle K Manske; Tammy Price-Troska; Steven C Ziesmer; Wai Lin; Bruce S Hostager; Susan L Slager; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Gail A Bishop; Anne J Novak
Journal:  J Exp Med       Date:  2010-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.